

# Atopic Dermatitis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A821E518065EN.html>

Date: November 2019

Pages: 597

Price: US\$ 2,000.00 (Single User License)

ID: A821E518065EN

## Abstracts

Atopic Dermatitis - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 12, 47, 25, 3, 57, 22 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Atopic Dermatitis (Atopic Eczema) - Overview

Atopic Dermatitis (Atopic Eczema) - Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment

Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Drug Profiles

Atopic Dermatitis (Atopic Eczema) - Dormant Projects

Atopic Dermatitis (Atopic Eczema) - Discontinued Products

Atopic Dermatitis (Atopic Eczema) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Table 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 10: Number of Products under Development by Universities/Institutes, H2 2019

Table 11: Products under Development by Companies, H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 17: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 18: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 19: Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 20: Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 21: Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 22: Products under Development by Universities/Institutes, H2 2019

Table 23: Number of Products by Stage and Target, H2 2019

Table 24: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 25: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 26: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 27: Number of Products by Stage and Mechanism of Action, H2 2019

Table 28: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 29: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 31: Number of Products by Stage and Route of Administration, H2 2019

Table 32: Number of Products by Stage and Molecule Type, H2 2019

Table 33: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H2 2019

Table 34: Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2019

Table 35: Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2019

Table 36: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, H2 2019

Table 37: Atopic Dermatitis (Atopic Eczema) - Pipeline by Afecta Pharmaceuticals Inc, H2 2019

Table 38: Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, H2 2019

Table 39: Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergan Plc, H2 2019

Table 40: Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, H2 2019

Table 41: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, H2 2019

Table 42: Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, H2 2019

Table 43: Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, H2 2019

Table 44: Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, H2 2019

Table 45: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Inc, H2 2019

Table 46: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, H2 2019

Table 47: Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019

Table 48: Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, H2 2019

Table 49: Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Table 50: Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, H2 2019

Table 51: Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, H2 2019

Table 52: Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, H2 2019

Table 53: Atopic Dermatitis (Atopic Eczema) - Pipeline by Azitra Inc, H2 2019

Table 54: Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, H2 2019

Table 55: Atopic Dermatitis (Atopic Eczema) - Pipeline by Biomimetix JV LLC, H2 2019

Table 56: Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, H2 2019

Table 57: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 58: Atopic Dermatitis (Atopic Eczema) - Pipeline by Boston Pharmaceuticals Inc, H2 2019

Table 59: Atopic Dermatitis (Atopic Eczema) - Pipeline by Botanix Pharmaceuticals Ltd, H2 2019

Table 60: Atopic Dermatitis (Atopic Eczema) - Pipeline by Calcico Therapeutics Ltd, H2 2019

## List Of Figures

### LIST OF FIGURES

Figure 1: Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019

### COMPANIES MENTIONED

Abate Med Inc

AbbVie Inc

Abeome Corp

Aclaris Therapeutics Inc

Afecta Pharmaceuticals Inc

Akaal Pharma Pty Ltd

Allergan Plc

Almirall SA

Amgen Inc

Amorepacific Corp

AOBiome LLC

Apimeds Inc

Arcutis Inc

Arena Pharmaceuticals Inc

Arrien Pharmaceuticals LLC

Asana BioSciences LLC

Aslan Pharmaceuticals Ltd

Astellas Pharma Inc

AstraZeneca Plc

Atrapos Therapeutics LLC



Azitra Inc  
Bausch Health Companies Inc  
Biomimetix JV LLC  
Blueberry Therapeutics Ltd  
Boehringer Ingelheim International GmbH  
Boston Pharmaceuticals Inc  
Botanix Pharmaceuticals Ltd  
Calcico Therapeutics Ltd  
Celgene Corp  
ChironWells GmbH  
Chugai Pharmaceutical Co Ltd  
Clayton Biotechnologies Inc  
Clevexel Pharma SAS  
CSA Biotechnologies LLC  
Cutanea Life Sciences Inc  
Daiichi Sankyo Co Ltd  
Dermata Therapeutics LLC  
Dermavant Sciences Inc  
DermBiont Inc  
Devonian Health Group Inc  
DongKoo Bio & Pharma Co Ltd  
DURECT Corp  
EHL Bio Co Ltd  
Eli Lilly and Co  
Evelo Biosciences Inc  
Evotec SE  
F. Hoffmann-La Roche Ltd  
Fountain Biopharma Inc  
Galapagos NV  
Galderma SA  
General Regeneratives Shanghai Ltd  
GI Innovation Co Ltd  
GlaxoSmithKline Plc  
Helix BioMedix Inc  
Hill Dermaceuticals Inc  
Hoth Therapeutics Inc  
Huons Co Ltd  
Ichnos Sciences Inc  
Immune Pharmaceuticals Inc

Incyte Corp  
Inflamalps SA  
Innovation Pharmaceuticals Inc  
Innovimmune Biotherapeutics Inc  
Japan Tobacco Inc  
Jiangsu Hengrui Medicine Co Ltd  
JiangSu Qyuns Therapeutics Co Ltd  
JW Pharmaceutical Corp  
Kang Stem Biotech Co Ltd  
Kine Sciences  
Kiniksa Pharmaceuticals Corp  
KoBioLabs Inc  
Krystal Biotech Inc  
Kv1.3 Therapeutics  
Kymab Ltd  
Kyowa Kirin Co Ltd  
Larix Bioscience LLC  
Lead Pharma Holding BV  
Lemonex Inc  
Leo Pharma AS  
Lipid Biologics LLC  
Lypanosys Pte Ltd  
Madam Therapeutics BV  
Matrisys Bioscience Inc  
MC2 Therapeutics AS  
Medicenna Therapeutics Corp  
Micareos BV  
Nektar Therapeutics  
Nepsone ehf  
Neuracle Science Co Ltd  
NeuroCycle Therapeutics GmbH  
Next Science Ltd  
NovaCell Technology Inc  
Novan Inc  
Novartis AG  
Oasis Pharmaceuticals LLC  
OliX Pharmaceuticals Inc  
Ondek Pty Ltd  
Orbis Biosciences Inc

Otsuka Holdings Co Ltd  
Pantherics Inc  
Pfizer Inc  
PHI Therapeutics Inc  
Polyrizon Ltd  
Portola Pharmaceuticals Inc  
Provectus Biopharmaceuticals Inc  
Pyramid Biosciences Inc  
Qurient Co Ltd  
Ralexar Therapeutics Inc  
RAPT Therapeutics Inc  
Regeneron Pharmaceuticals Inc  
Ribomic Inc  
SCM lifescience Co Ltd  
Seelos Therapeutics Inc  
Servatus Ltd  
Shaperon Inc  
Shulov Innovative Science Ltd  
Sienna Biopharmaceuticals Inc  
Signum Biosciences Inc  
Signum Dermalogix Inc  
Sosei Heptares  
Spherium Biomed SL  
StemRIM Inc  
sterna biologicals Gmbh & Co KG  
Suzhou Connect Biopharmaceuticals Ltd  
Suzhou Zelgen Biopharmaceutical Co Ltd  
TaiwanJ Pharmaceuticals Co Ltd  
Temisis Therapeutics  
The Geneva Biotech Center SA  
Therabest Co Ltd  
Tianjin Hemay Bio-Tech Co Ltd  
Tolerys SA  
Torrent Pharmaceuticals Ltd  
Transdermal Therapeutic Technologies LLC  
Union Therapeutics AS  
Vasomune Inc  
VivaCell Biotechnology Espana SL  
Voronoi

vTv Therapeutics Inc  
Welichem Biotech Inc  
XBiotech Inc  
Xencor Inc  
Zhejiang I-Biological Technology Co Ltd

## I would like to order

Product name: Atopic Dermatitis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A821E518065EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A821E518065EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970